Retinal changes in Alzheimer's disease— integrated prospects of imaging, functional and molecular advances

Alzheimer's Disease (AD) is a devastating neurodegenerative disorder of the brain, clinically characterised by cognitive deficits that gradually worsen over time. There is, at present, no established cure, or disease-modifying treatments for AD. As life expectancy increases globally, the number of individuals suffering from the disease is projected to increase substantially. Cumulative evidence indicates that AD neuropathological process is initiated several years, if not decades, before clinical signs are evident in patients, and diagnosis made. While several imaging, cognitive, CSF and blood-based biomarkers have been proposed for the early detection of AD; their sensitivity and specificity in the symptomatic stages is highly variable and it is difficult to justify their use in even earlier, pre-clinical stages of the disease. Research has identified potentially measurable functional, structural, metabolic and vascular changes in the retina during early stages of AD. Retina offers a distinctively accessible insight into brain pathology and current and developing ophthalmic technologies have provided us with the possibility of detecting and characterising subtle, disease-related changes. Recent human and animal model studies have further provided mechanistic insights into the biochemical pathways that are altered in the retina in disease, including amyloid and tau deposition. This information coupled with advances in molecular imaging has allowed attempts to monitor biochemical changes and protein aggregation pathology in the retina in AD. This review summarises the existing knowledge that informs our understanding of the impact of AD on the retina and highlights some of the gaps that need to be addressed. Future research will integrate molecular imaging innovation with functional and structural changes to enhance our knowledge of the AD pathophysiological mechanisms and establish the utility of monitoring retinal changes as a potential biomarker for AD

Hydrogen injection in a dual fuel engine fueled with low-pressure injection of methyl ester of peruvenia thevetia [MEPT] for diesel engine maintenance application

The present work is mapped to scrutinize the consequence of biodiesel and gaseous fuel properties, and their impact on compression-ignition (CI) engine combustion and emission characteristics in single and dual fuel operation. Biodiesel prepared from non-edible oil source derived from Thevetia peruviana belonging to the plant family of Apocynaceaeis. The fuel has been referred as methyl ester of Thevetia peruviana (METP) and adopted as pilot fuel for the effective combustion of compressed gaseous fuel of hydrogen. This investigation is an effort to augment the engine performance of a biodiesel-gaseous fueled diesel engine operated under varied engine parameters. Subsequently, consequences of gas flow rate, injection timing, gas entry type, and manifold gas injection on the modified dual-fuel engine using conventional mechanical fuel injections (CMFIS) for optimum engine performance were investigated. Fuel consumption, CO, UHC, and smoke formations are spotted to be less besides higher NOx emissions compared to CMFIS operation. The fuel burning features such as ignition delay, burning interval, and variation of pressure and heat release rates with crank angle are scrutinized and compared with base fuel. Sustained research in this direction can convey practical engine technology, concerning fuel combinations in the dual fuel mode, paving the way to alternatives which counter the continued fossil fuel utilization that has detrimental impacts on the climate